This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- 18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer
- 18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice
- The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions
- Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography
- Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer.
- Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
- Primary Systemic Therapy of Breast Cancer
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- FDG-PET and Beyond: Molecular Breast Cancer Imaging
- 18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy
- Bone Imaging in Metastatic Breast Cancer
- Changes in Blood Flow and Metabolism in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy
- Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
- 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
- Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy
- Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients
- Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients with Breast Cancer: The Referring Physician's Perspective
- 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer
- A Tabulated Summary of the FDG PET Literature
- Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations
- Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
- Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
- Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose